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Abstract. An association between late-stage hepatosplenic schistosomiasis and endomyocardial fibrosis (EMF) has
been suggested but not proven. We present the case of a 12-year-old Ugandan boy with striking comorbidities, including
advanced periportal fibrosis caused by Schistosoma mansoni infection and right ventricular EMF, and discuss the possible
correlation between both diseases.
INTRODUCTION
In sub-Saharan Africa (SSA), infection with Schistosoma
mansoni typically gives rise to intestinal and hepatosplenic
disease. This disease originates from immunological lesions
and fibrotic granulomata forming to egg toxins or around
tissue-trapped eggs.1 With established periportal fibrosis, end-
stage organ damage results in the gradual development of
collateral circulation.1 It is this evolving portocaval circulation
that permits dissemination of schistosome eggs, egg toxins, or
activated eosinophils to other parts of the body that might
otherwise become trapped in the periportal sinuses and in
so doing, likely leads to right-side heart complications, such
as fibrosis.2
Endomyocardial fibrosis (EMF) was first described in
Uganda in 1948. It represents a significant local health burden,
although its etiology remains enigmatic.3 EMF can feature
right and/or left ventricular endocardial fibrosis extending to
the inner third of the myocardium. It typically affects the apex
and inflow regions,3 leading to restrictive cardiomyopathy and
cardiac failure. Right ventricular EMF classically presents with
elevated jugular venous pressure, ascites, and hepatomegaly,
whereas left ventricular EMF presents with severe pulmonary
hypertension.4 Prognosis is poor, with death commonly occur-
ring within 2 years of diagnosis.3
The worldwide distribution of EMF is puzzling and includes
countries like Brazil, China, India, Mozambique, and Nigeria,
and there are imported cases reported in the United Kingdom,
Europe, and the United States.4,5 Several theories of its etiol-
ogy have been postulated3,5: associations have been found with
eosinophilia (> 30% of patients5) possibly linked to helminth
infections, such as lymphatic filariasis, poverty in general, and
low-protein or imbalanced diets in particular.3,6,7
Although associations between hepatosplenic schistosomi-
asis and EMF have been suggested in Egypt and Brazil, a
common pathogenic mechanism remains uncertain.2,8 We
describe the case of a Ugandan child with EMF and advanced
liver fibrosis and hypothesize that both diseases are unlikely to
be coincidental. To our knowledge, this patient is the youngest
child reported with these striking concomitant morbidities.
CASE HISTORY
In November of 2012, while conducting an epidemiological
survey of schistosomiasis around Lake Albert, Uganda, an
11-year-old boy was brought to the attention of the field
medical team. He was from the Alur tribe and had been born
and raised in the area. S. mansoni-related morbidities (intesti-
nal and hepatosplenic disease) are hyperendemic in his village
(Walukuba), with infection prevalence and intensity near the
highest recorded in recent parasitological cross-sectional sur-
veys in Uganda.9
On examination, the boy appeared chronically ill, with
marked icterus and dry mucous membranes. His abdomen
was grossly distended with massive hepatosplenomegaly,
although he did not have peripheral edema. Cardiovascular
examination revealed normal heart sounds with good periph-
eral pulses. No increased jugular venous pressure was noted,
and his chest was clear. Parasitological investigations con-
firmed egg patent S. mansoni infection by Kato–Katz fecal
smear with 5,000 eggs/1 g stool (epg) and a positive urine
circulating cathodic antigen (CCA) rapid diagnostic test
(Rapid Medical Diagnostics, South Africa). His rapid human
immunodeficiency virus (HIV) test was negative (Determine
HIV-1/2; World Health Organization [WHO] donation). No
additional investigations were undertaken at that time because
of a lack of resources. He was treated with a standard dose of
praziquantel (40 mg/kg).
One year later, the team returned and found that there had
been no clinical improvement in the boy’s hepatosplenic
disease. He was noted to be stunted for age: weight = 30 kg
and height = 131 cm (−1 SD body mass index-for-age Z score;
−2 SD height-for-age Z score). He had S. mansoni egg patent
infection, with 24 epg and a strongly positive urine CCA.
Finger-prick hemoglobin concentration was 11 g/dL by porta-
ble photometer (Hemocue, United Kingdom). A malaria rapid
diagnostic test for Plasmodium spp. was negative. Portable
abdominal ultrasound using a 3.5-MHz convex probe (Aloka
3500; Aloka, United Kingdom) showed hepatosplenomegaly,
moderate ascites, portal vein dilatation, and advanced
periportal fibrosis with ruff around the portal bifurcation.
These findings represent stage D of the WHO classification10
for hepatosplenic schistosomiasis (Figure 1A).
Examination of the heart with the same ultrasound scanner
showed a pericardial effusion of uncertain etiology, and the
child was taken back to Kampala with the field team for addi-
tional investigations. At Mulago National Referral Hospital,
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a transthoracic echocardiogram revealed fibrosis of the right
ventricular endocardium with a grossly dilated right atrium, a
small anterior pericardial effusion of < 2.0 cm, and a normal
left ventricle. The ejection fraction (E/F) was 52% (reference =
40–70%) with fractioning shortening (F/S) of 26% (reference =
25–45%). There was borderline normal systolic function,
impaired diastolic function, and moderate functional tricuspic
regurgitation caused by gross dilatation of right atrium
(Figure 1B).
Extended laboratory investigations carried out in the same
referral hospital revealed a total white blood cell (WBC) count
of 9.1 + 103/mL (reference = 4.0–11.0 + 103/mL) with a raised
eosinophil count of 3.58 + 103/mL (reference = 0.04–0.40 +
103/mL). Serum bilirubin was 1.2mg/dL (reference = 0–1mg/dL),
albumin was 28 g/L (reference = 35–50 g/L), and total
protein was 67.7 g/L (reference = 63–83 g/L). Hepatitis B
surface antigen and rapid Hepatitis C antibody test were
negative. Chest radiograph showed striking cardiomegaly.
The boy was treated again with a dose of praziquantel and
started on daily propanolol (1 mg/kg). At follow-up 28 days
later, he reported feeling better with more energy. There were
no detectable S. mansoni eggs in his stool, although the urine
CCA test remained weakly positive. A transthoracic echocar-
diogram 1 month later showed mildly improved cardiac func-
tion, with E/F of 64% and F/S of 34%. He remains on
treatment with daily propanolol and will be reviewed again in
November of 2014.
DISCUSSION
Although this 12-year-old boy is young to present with
advanced schistosomiasis, it is not uncommon around Lake
Albert, where 17% of children under 9 years old are reported
to have some degree of liver fibrosis (Bustinduy AL and
others, unpublished data). Despite yearly praziquantel distri-
bution to children in villages along this part of the shoreline,
we learned through interview that this child did not receive
his first dose of treatment until 2011. Children here are typi-
cally infected very soon after birth and can develop chronic
schistosomiasis at an early age. It is, therefore, most likely that,
in this boy’s case, the hepatofibrotic disease preceded EMF.
Furthermore, the boy’s eosinophilia is unusual, because it is
generally associated with early schistosomal infection rather
than advanced periportal fibrotic disease. Eosinophils have
the capacity to degranulate on contact with antibody-coated
surfaces, such as tissues or parasites, and therefore, a raised
eosinophil count may represent evidence of ongoing damage to
the liver, heart, or both organs. Additional myocardial dam-
age could be triggered by shunted schistosome eggs through
the portocaval collateral circulation, which was postulated in
adult Egyptian patients with schistosomiasis and EMF.2
Alternative etiologies for eosinophilia, such as Strongyloides,
were not found.
Finding this child with advanced hepatosplenic disease and
right ventricular EMF allows us to speculate more broadly on
the etiology of EMF in Uganda. Both clinical entities are
diseases of poverty and share a markedly profibrotic state
with a strong relationship to eosinophilia. The high prevalence
of EMF found in schistosomiasis-endemic countries, such as
Uganda, Mozambique, and Nigeria, suggests that there may
be an unidentified link.6,7,11 Therefore, cause or coincidence
remains an open question in this impoverished part of Uganda,
where hepatosplenic schistosomiasis is particularly rife and
there is a dearth of cardiovascular disease surveillance.
Previously, only Brazil and Egypt had published cases with
a suggested association between schistosomiasis and EMF.
However, the patient selection may have been highly skewed,
because all cases presented in cardiac failure. Little inference
can, therefore, be made in earlier stages clinical interactions.2,8
Because EMF has a spectrum of disease (acute, subacute, and
chronic), finding patients only in the burned out phase likely
underreports those in less severe stages.12 In a population-
based study in Brazil of 152 patients with schistosomiasis, no
EMF was detected, but this study may have been underpow-
ered to detect a disease that may not be that prevalent.13
If there is, indeed, an association between these diseases, it
would be important to unveil it for several reasons. Under-
standing the interplay between schistosomiasis with EMF in
SSA would change our perception of the burden of disease,
bringing together new dialogue between cardiologists, infec-
tious disease specialists, and epidemiologists. If this link is
proven by subsequent epidemiological studies or experimental
studies in laboratory models, it might lead to a future preven-
tion strategy for EMF, which is presently lacking. For example,
Figure 1. (A) Two-dimensional echocardiogram showing right ventricular (RV) fibrosis with gross right atrium (RA) dilatation and normal
left ventricle (LV). (B) Abdominal ultrasound showing enlarged portal vein (PV) with periportal ruff and fibrosis stage D WHO classification.
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if regular praziquantel treatment could prevent portocaval cir-
culation remodeling, lower eosinophilia levels, and reduce cir-
culating egg toxins, the occurrence of EMFmight be diminished
or even averted. Because preventive chemotherapy campaigns
delivering praziquantel en masse form the foundation of schis-
tosomiasis control and because such programs are encouraged
to document schistosomiasis-related morbidity, efforts should
be mindful of a potential impact on cardiovascular disease.
In this scenario, we conclude that, although possible, it is
unlikely that EMF and schistosomiasis are completely indepen-
dent from one another, and this connection should be explored
in greater detail. With this case report, our hope is to fuel
interest in this very intriguing tandem of neglected diseases in
SSA and encourage well-designed prospective studies address-
ing the combination of schistosomiasis and EMF. We, there-
fore, strongly advocate the use of future ultrasound and
echocardiographic screening to not only quantify the burden of
EMF but also, identify likely triggers, such as schistosomiasis.
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